The Discovery
Diabetes Without Answers
A Growing Crisis With Shrinking Options
Key moment
10+ million Americans with type 2 diabetes by 1990
By the early 1990s, type 2 diabetes was spreading across America like wildfire. More than 10 million people had it, and the number was climbing every year. The treatments available were frustrating at best and dangerous at worst.
Insulin injections were the gold standard, but they caused weight gain and could make blood sugar crash to dangerously low levels. Pills like sulfonylureas pushed the pancreas harder and harder to make insulin, eventually wearing it out. Metformin helped, but many patients needed more.
Doctors were stuck. They needed a drug that could lower blood sugar without the constant risk of crashes, without causing weight gain, and ideally one that could help the exhausted pancreas recover. That drug existed — but it was hiding in the mouth of a poisonous lizard in the Arizona desert.
The Breakthrough
The Bronx Lab
A Scientist, A Catalog, and A Lizard
Key moment
Venom ordered by mail from a Utah serpentarium
Dr. John Eng was an endocrinologist at the Veterans Affairs Medical Center in the Bronx, New York. He had developed a technique to screen animal venoms for new hormones — and he was looking for something no one else thought to search for.
Earlier NIH research had shown that Gila monster venom could make the pancreas enlarge. Eng was fascinated. The Gila monster is one of only two venomous lizards on Earth. It eats just three or four times a year, yet somehow keeps its blood sugar perfectly controlled between meals. Eng suspected the answer was in its venom.
He ordered dried venom samples from a serpentarium in Utah — through a mail-order catalog, of all things. Working in his modest Bronx lab, he ran his chemical screening tests. In 1992, the results came back: the venom contained a brand-new hormone he named exendin-4. It looked remarkably similar to human GLP-1 — but with one critical difference. While natural GLP-1 fell apart in the bloodstream in two minutes, exendin-4 lasted for hours. The lizard had already solved the problem that was stumping every scientist in the field.
The Trials
Nobody Wanted It
A Discovery Abandoned By Its Own Government
Key moment
VA refused to patent — Eng paid for it himself
What happened next would frustrate Eng for years. He brought his discovery to the VA, expecting excitement. Instead, they showed no interest in patenting exendin-4. The government agency that funded his lab saw no commercial potential in a hormone from lizard spit.
So Eng took an extraordinary step: he paid for the patent himself, using his own money. Then he began knocking on doors at pharmaceutical companies. One after another, they turned him down. A diabetes drug from lizard venom? It sounded too strange, too risky.
For nearly three years, Eng struggled. Then, in 1996, at a scientific meeting in San Francisco, he pinned up a poster showing how exendin-4 lowered blood sugar in diabetic mice. A small biotech company called Amylin Pharmaceuticals — based in San Diego and already working on a similar gut hormone called amylin — saw the poster and made a deal. They would turn Eng's lizard hormone into a real drug.
Amylin created a synthetic version called exenatide, identical to the natural Gila monster peptide, and began the long, expensive process of clinical trials.
The Crisis
The Pancreatitis Shadow
Success Meets Suspicion
Key moment
First-ever GLP-1 drug approved — then pancreatitis fears hit
On April 28, 2005, the FDA approved Byetta — making exenatide the first GLP-1 drug in history. Patients injected it twice daily before meals, and the results were impressive: lower blood sugar, weight loss instead of weight gain, and far fewer dangerous blood sugar crashes than insulin.
But success brought scrutiny. In 2007, reports of acute pancreatitis — painful, sometimes deadly inflammation of the pancreas — began appearing in Byetta users. The FDA added warnings to the label. Headlines questioned whether the drug was safe. Some researchers pointed to a possible link between GLP-1 drugs and pancreatic cancer, though the evidence was thin.
Amylin Pharmaceuticals fought back with data showing the pancreatitis rate was no higher than in diabetic patients not taking the drug. But the damage to public confidence was real. The company's stock dropped. Doctors hesitated to prescribe it. The first GLP-1 drug ever approved was fighting for its reputation.
The Legacy
The Door It Opened
From Twice Daily to Once Weekly — and Beyond
Key moment
Golden Goose Award for curiosity-driven research that changed medicine
Amylin didn't give up. They developed Bydureon — an extended-release version of exenatide that patients needed only once per week instead of twice daily. The FDA approved it in 2012. The convenience was a game-changer, and it proved that GLP-1 drugs could be redesigned for easier use.
But exenatide's greatest legacy isn't the drug itself — it's what it proved was possible. By showing that a GLP-1 drug could safely lower blood sugar, cause weight loss, and avoid dangerous crashes, Byetta opened the floodgates. Liraglutide (Victoza) followed. Then semaglutide (Ozempic, Wegovy). Then tirzepatide (Mounjaro). Each one built on the foundation that a stubborn scientist in a Bronx VA hospital had laid.
In 2013, Eng received the Golden Goose Award — given to scientists whose quirky, curiosity-driven research led to major breakthroughs. The committee's message was clear: sometimes the most important discoveries come from the most unexpected places. Like the mouth of a poisonous desert lizard.
Today, GLP-1 drugs are the fastest-growing class of medicines in the world. It all started with a mail-order venom sample and a scientist who wouldn't take no for an answer.
Peptide history · 1992
Exenatide (Byetta / Bydureon)
The Lizard Venom That Launched a Diabetes Revolution
A poisonous desert lizard, a stubborn scientist in a Bronx VA hospital, and a government that refused to patent the discovery — this is the unlikely story of how Gila monster spit became one of the most important diabetes drugs ever made.
Found in Gila monster venom by Dr. John Eng
First GLP-1 drug ever approved (Byetta)
53% identical to human GLP-1
Daltons
Heloderma suspectum venom
US peak in 2008
Dr. John Eng
The Lizard Venom Detective · Bronx VA Medical Center
Working alone in a modest VA hospital lab in the Bronx, Eng ordered dried Gila monster venom from a Utah serpentarium through a catalog. In 1992, he discovered exendin-4 — a hormone in the venom that controlled blood sugar. When the VA refused to patent it, Eng paid for the patent himself and spent years finding someone willing to develop it into a drug.
I thought the VA would be excited. Instead, they showed no interest in patenting it. So I did it myself. I believed in this molecule.
Dr. Jean-Pierre Raufman
The First Clue · National Institutes of Health
In the 1980s, Raufman at the NIH discovered that Gila monster venom could make the pancreas grow larger. This early finding caught John Eng's attention and set him on the path to studying what was hiding in the lizard's spit.
We noticed something strange about Gila monster venom — it was making pancreatic cells grow and multiply. Something in that venom was sending powerful signals.
Amylin Pharmaceuticals Team
The Believers · San Diego, California
After every major drug company turned Eng down, the small biotech startup Amylin Pharmaceuticals took a chance on exendin-4. Their team turned the lizard hormone into a synthetic drug called exenatide, ran the clinical trials, and brought Byetta to market in 2005 — creating an entirely new class of diabetes medicines.
Everyone told us a diabetes drug from lizard venom was crazy. We thought it was brilliant.
14 milestones, 1952 – 2014.
- 1952Scientists first study Gila monster venom and notice it affects the digestive system
- 1983GLP-1 is discovered hiding in the glucagon gene by Joel Habener's team
- 1986NIH researcher Raufman shows Gila monster venom can make the pancreas grow
- 1990John Eng begins screening Gila monster venom for hormones at the Bronx VA
- 1992Eng discovers exendin-4 in Gila monster venom — 53% identical to human GLP-1
- 1993VA refuses to patent the discovery; Eng files and pays for the patent himself
- 1996Amylin Pharmaceuticals licenses exendin-4 after seeing Eng's poster at a conference
- 2000Clinical trials of synthetic exenatide (Byetta) begin in humans
- 2005FDA approves Byetta — the first GLP-1 receptor agonist drug in history
- 2007FDA adds pancreatitis warning to Byetta's label after post-market reports
- 2008Byetta US sales peak at $678 million
- 2012FDA approves Bydureon — the first once-weekly GLP-1 drug
- 2013John Eng receives the Golden Goose Award for his lizard venom discovery
- 2014AstraZeneca acquires rights; Bydureon BCise auto-injector launched
Imagine a lizard that eats only three or four times a year. To survive long stretches without food, the Gila monster makes a special substance in its spit that controls blood sugar with incredible precision. Exenatide is a lab-made copy of that lizard hormone — and it works in humans too.
Molecular structure
- Amino Acids
- 39
- Molecular Weight
- 4,187 Da
- Similarity to GLP-1
- 53%
- Half-life (Byetta)
- ~2.4 hours
- Formula
- C₁₈₄H₂₈₂N₅₀O₆₀S
- DPP-4 Resistant
- Yes
2008 — Byetta alone
April 28, 2005
Within first 5 years of approval
Byetta and Bydureon
Real stories, real lives
Robert Chen
I'd been on three different diabetes pills and my numbers were still terrible. My doctor suggested Byetta, and I remember thinking — a drug from lizard venom? Really? But within two months my blood sugar was under control for the first time in years. I lost 12 pounds too. That lizard saved my life.
Linda Holloway
The twice-daily Byetta injections were hard to keep up with. When Bydureon came out — one shot per week — it changed everything. I set a reminder every Sunday morning, take my shot, and don't think about it until the next week. My last three checkups have been the best numbers I've had in a decade.
The future of Exenatide
- Alzheimer's Disease TrialsPhase 3
Exenatide is being tested as a treatment for Alzheimer's and Parkinson's disease — researchers believe it may protect brain cells
- Next-Generation Lizard PeptidesResearch
Scientists are studying other Gila monster venom components for potential new drugs
- Improved Delivery SystemsDevelopment
Implantable pumps and longer-acting formulations to reduce injection frequency even further
- Combination TherapiesClinical Trials
Exenatide combined with other hormones for even better blood sugar and weight control
Be inspired
The story of Exenatide is ultimately about the relentless pursuit of better medicine for humanity.
Continue the legacy. The next breakthrough could be yours.